top of page
Gary Portrait (2)_edited.jpg

Gary L. Jones
PHD, MD, FAAN

Upon completion of a B.S. in chemistry Dr. Jones pursued a Ph.D. in Pharmacology, under the mentorship of Dixon M. Woodbury, Ph.D. at the University of Utah.  A two year post-doctoral fellowship in molecular pharmacology followed, working with Dr. Woodbury and Frank Harris, Ph.D. of the Physics Department at the at the University of Utah.  His focus was the application of computational chemistry in the  QSAR of antiepileptic drugs. 

 
In 1977 Dr. Jones took an academic position at the University of North Texas Health Science Center. He taught medical school pharmacology and developed several graduate level courses in pharmacology.  His continued his research in anticonvulsant QSAR and drug discovery, and

acquired an interest in electron paramagnetic resonance spectroscopy which he applied in his research.  Dr. Jones synthesized some novel spin labels and compounds used in his epilepsy research.  During his eight year tenure Dr. Jones published peer reviewed research papers and reviews, and was promoted to Associate Professor.
 

Dr. Jones returned to the Utah where he obtained a medical degree in 1987, and completed a neurology residency in 1991.  He continued to publish in the peer reviewed literature, and was a co-investigator with Dr. Woodbury during this time.
 

Dr. Jones chose a career in clinical neurology in 1991 and became the first neurologist to serve in all of  southern Utah.  For five years much of his time was divided between the emergency room and the intensive care unit, for which he was largely responsible.  With FDA approval of tissue plasminogen activator (TPA) use in acute stroke in 1996 Dr. Jones designed the TPA in  acute stroke protocol in St. George, and was on call 24/7 for the treatment of any qualifying patient. 

 

After Dr. Jones was able to lighten his acute care responsibilities, he built a successful multi-specialty clinic.  Care was provided not only by a staff of neurologists, but oncology, cardiology, pulmonology, internal medicine and family practice services were also provided.  He acquired the first high field strength MRI in southern Utah, and the first PET-CT scanner in Utah. 

 

Dr. Jones maintained a large basic science laboratory in his clinic; where he continued research in epilepsy, but also developed interests in neuroprotection in acute stroke.  He published several papers and patents during this time, but with acquisition of the PET-CT Dr. Jones’s interests in Alzheimer’s disease (AD) began to evolve.  He had already acquired over 15 years of clinical experience with AD patients.  Over time AD became his dominant research focus; and this is when he developed his present strategy in AD prevention.

 

As Dr. Jones decided to devote full time to basic neuroscience research with a focus on AD he sold the clinic business to his colleagues.  A few years later a new medical school purchased their land and clinic, and the laboratory was moved to a new, and larger facility.

Bibliography

(A) = abstract; (P) = peer reviewed research article;  (R) = Invited review/book chapter; (O)  = Other

 

-Jones GL, Kemp JW:  Characteristics of the Hydrogen Bonding Interactions of Diphenylhydantoin with Nucleic Acids and their Components.  Fed Proc 31:570, 1972.  (A)

-Jones GL, Woodbury DM:  Effects of Diphenylhydantoin on Protein and Amino Acid Metabolism in Rat Cerebral Cortex. Pharmacologist 16:256, 1974.  (A)

-Jones GL, Kemp JW:  Characteristics of the Hydrogen Bonding Interactions of Substituted Hydantoins with 9-Ethyladenine.  Molec Pharmacol 10:48-56, 1974.  (P)

-Jones GL, Woodbury DM:  A Spin-Label Study of Phenothiazine Perturbations of the Protein and Lipid Phases of Erythrocyte Membranes. Pharmacologist 18:240, 1976.  (A)

-Jones GL, Woodbury DM:  Effects of Diphenylhydantoin and Phenobarbital on Protein Metabolism in the Rat Cerebral Cortex.  Biochem Pharmacol 25:53-61, 1976.  (P)

-Jones GL, Woodbury DM:  An Alternative Interpretation of the Heterogenous Electron Spin Resonance Spectrum of the Protein Spin Label 4-Maleimido-2,2,6,6--        ----  Tetramethylpiperidinooxyl in Erythrocyte Ghosts. Pharmacologist 19:162, 1977.  (A)

-Jones GL:  Antisickling Effects of Beta-Diethylaminoethyl Diphenylpropylacetate (SKF 525-A).  Pharmacologist 20:204, 1978.  (A)

-Jones GL, Woodbury DM:  Spin-Label Study of Phenothiazine Interactions with Erythrocyte Ghost Membranes:  A Possible Membrane-Mediated Antisickling Action. J. Pharmacol   Exp Ther 207:203-311, 1978.  (P)

-Jones GL, Woodbury DM:  Reappraisal of the Electron Spin Resonance Spectra of Maleimide and Iodoacetamide Spin Labels in Erythrocyte Ghosts.  Arch Biochem Biophys 190:611-616, 1978.  (P)

-Jones GL:  Spin-Label Study of Hemoglobin-Membrane Interactions in Normal and Sickle Erythrocytes.  Proc West Pharmacol Soc 22:79-88, 1979.  (A)

-Jones MF, Jones GL, Amato RT, Peyton GA, Wimbish GH: Reassessment of the Anticonvulsant Activity of  α,α−Diphenylsuccinimide.  Proc West Pharmacol Soc 23:171-174, 1980.  (A)

-Wimbish GH, Jones GL, Amato RJ, Peyton GA: Comparison of the Anticonvulsant Activities and Brain Concentrations of Cyheptamide and Carbamazepine. Proc West Pharmacol Soc 23:75-79, 1980.  (A)

-Jones GL:  Spin-Label Study of Phenothiazine Interactions with the Lipid Phase of Erythrocyte Membranes.  Proc West Pharmacol Soc 23:399-404, 1980.  (A)

-Jones GL:  Anticonvulsant Quantitative Structure-Activity Relationships.  Pharmacologist 23:182, 1981.  (A)

-Jones GL, Amato RJ, Wimbish GH, Peyton GA:  Comparison of Anticonvulsant Potencies of Cyheptamide, Carbamazepine and Phenytoin.  J. Pharm Sci 70:618-620, 1981.  (P)

-Jones GL:  Quantitative Structure-Activity Relationships of Convulsant 1,5-Cyclopolymethylenetetrazoles.  Fed Proc 41:1051, 1982.  (A)

-Jones GL, Woodbury DM:  “Principles of Drug Action: Structure-Activity Relationships and Mechanisms” In Antiepileptic Drugs, 2nd ed (Woodbury DM, Penry JK, Pippenger CE, eds), Raven Press, New York, pp 88-109, 1982. (R)

-Jones GL, Woodbury DM:  Anticonvulsant Structure-Activity Relationships:  Historical Development and Probable Causes of Failure.  Drug Develop Res 2:333-355, 1982.  (P)

-Amato RJ, Jones GL:  Reassessment of the Anticonvulsant Activity of Diphenylacetylurea.  Drug Develop Res 2:47-53, 1982.  (P)

-Jones GL, Wimbish GH, McIntosh WE: Phenytoin: Basic and Clinical Pharmacology.  Med Res Rev 3(#4):383-434, 1983.  (R)

-Jones GL, Amato RJ, Jones MF:  Diphenylsuccinimide: Anticonvulsant and Hydrophobic Properties.  J Pharm Sci 73:310-313, 1984.  (P)

-Jones GL, Wimbish GH:  “Hydantoins” in Handbook of Experimental Pharmacology, Vol 74, Antiepileptic Drugs (Frey HH, Janz D, eds), Springer-Verlag, Berlin, pp 351-419, 1985.  (R)

-Jones GL, Woodbury DM:  “Biochemistry” in Handbook of Experimental Pharmacology, Vol 74, Antiepileptic Drugs (Frey HH, Janz D, eds), Springer-Verlag, Berlin, pp 245-263, 1985.  (R)

-Jones GL:  Chicken Soup.  Bull Ut Med Assoc 33(#4):8, 1985.  (O)

-Jones GL:  Toward a Creative Curriculum.  Bull Ut Med Assoc 36(#12):6, 1988.  (O)

-Jones GL:  Life's Little Problems.  Bull Ut Med Assoc 37(#10):11, 1989.  (O)

-Jones GL:  Anticonvulsant Potency and Toxicity of  5,5-Diphenyl-2,4-Oxazolidinedione.  Drug Develop Res 21:19-27, 1990.  (P)

-Jones GL, Matsuo F, Baringer JR, Reichert WH:  Valproic Acid-Associated Encephalopathy. West J Med 153:199-202, 1990.  (A)

-Jones GL, Azzaoui K:  1,4-Dihydropyridine (DHP) Structure-Activity Relationships (SAR).  FASEB Journal 14:8, A1394, 2000.  (A)

-Azzaoui K, Jones GL:  Predicting the Maximum Electroshock-Induced Seizure Using Quantitative Structure-Activity Relationships of Anti-Convulsant Compounds.  FASEB Journal 14:8, A1394, 2000.  (A)

-Jones GL, Azzaoui K:  1,4-Dihydropyridine (DHP) Structure-Activity Relationships (QSAR):  Electron Transfer as a Possible Mode of Action.  Epilepsia 41: Supplement 7, p. 33, 2000.  (A)

bottom of page